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Background: Guidelines promote risk scores (CHADS2, CHA2DS2-VASc) to aid clinical decision-making. Global real-life data are needed to profile 
risk and thromboprophylaxis use among newly diagnosed AF patients at risk for stroke.
Methods: GARFIELD is a global registry of ≥55,000 patients enrolled as 5 sequential prospective cohorts (incl. 1 retrospective validation group 
in cohort 1) at >1000 sites in up to 50 countries. Eligible patients are ≥18 yr, recently diagnosed with nonvalvular AF, with ≥1 additional stroke risk 
factor. Data from 10,135 subjects (mean 70.1 yr; 43.2% women) from cohort 1 are presented.
Results: 3850 (38%) patients were ≥75 yr; 3401 (34%) were 65-74 yr. Prevalence of hypertension was 78%, heart failure 19%, diabetes 22%, 
stroke/TIA 14%, MI/unstable angina 10% and peripheral artery disease 6.9%. Oral anticoagulants (OAC) were used in 48%, aspirin in 25% and no 
antithrombotic therapy in 13%. Mean CHADS2 and CHA2DS2-VASc scores were 1.8 and 2.9, respectively. Based on CHADS2 and CHA2DS2-VASc 
scores, 55.3% and 81.3%, respectively, would be defined as high risk and OAC should be prescribed, but OAC is clearly underutilized with little 
relationship to stroke risk (Table). 
Variable
Total cohort
n (%)
OAC prescribed Aspirin No antithrombotic therapy Both OAC plus aspirin
CHADS2
0 855 (8.4) 38.2% 31.8% 20.8% 9.1%
1 3674 (36.3) 46.5% 27.4% 15.0% 11.1%
≥2 5599 (55.3) 51.2% 22.2% 9.8% 16.8%
CHA2DS2-VASc
0 341 (3.4) 34.6% 34.9% 22.0% 8.5%
1 1552 (15.3) 43.9% 28.7% 16.8% 10.6%
≥2 8235 (81.3) 49.8% 23.8% 11.4% 15.0%
Conclusion: GARFIELD provides real-world validated, rigorous data on AF treatment and outcomes globally. There was a strong relationship between 
prescribing of antithrombotics and stroke risk stratification, but OACs are used inappropriately in a large proportion of AF patients
